From "buy, buy, and buy" to "sell, sell, and sell," this pharmaceutical company sold the equity of four subsidiaries during the year

On October 7, Fosun Pharma issued an announcement stating that it intends to transfer its 29.
02% stake in Yaneng Bio-Bio to the buyer for a consideration of approximately 1.
596 billion yuan, and transfer its Jinshi shares to a subject jointly designated by the buyer and Yaneng Bio-Bio 100% of the equity of the Medical Inspection Institute; Yaneng Bio will be converted from a holding subsidiary to an associated company
.
It is understood that Yaneng Biological and its holding subsidiaries are mainly engaged in the research and development, production, sales and technical services of in vitro diagnostic reagents and supporting testing instruments.
Jinshi Medical Inspection Institute mainly provides supporting services for Yaneng Biological products and integrates with them.
Operation
.
Fosun Pharma stated that since 2020, the company has actively promoted the sorting of assets and businesses in the diagnostics sector, accelerating integration, coordination, and integration of operations
.
The funds received this time will be mainly used for the follow-up new track layout, product research and development, base construction and market investment of the diagnostics sector to promote the long-term sustainable development of the diagnostics sector
.
It is worth mentioning that Fosun Pharma has made continuous moves during the year.
The sale of the subsidiary is already Fosun Pharma’s fourth move from 2021 to the present
.
Prior to this, Fosun Pharma also announced plans to sell 25% of Tianjin Pharmaceutical, 100% of Foshan Chanxi, and 75% of Taizhou Zhedong Medical Care Investment
.
According to statistics, after the completion of the above-mentioned transactions, Fosun Pharma will sell the equity of the four subsidiaries and withdraw funds of 4.
132 billion yuan
.
Fosun Pharma has always adopted “buy, buy, and buy” as the company’s main strategy.
Now it has started to “sell, sell and sell.
” The company stated that it is mainly to optimize assets or focus on its main business.
The proceeds from the sale of equity will be used to supplement operating funds and return Interest-bearing debt
.
At the same time, the company is also accelerating innovation and transformation
.
The 2021 semi-annual report shows that the company achieved operating income of 16.
952 billion yuan in the first half of this year, a year-on-year increase of 20.
85%, and deducted non-net profit of 1.
570 billion yuan, a year-on-year increase of 20.
38%
.
In fact, the transition from "buy, buy, and buy" to "sell, sell, and sell" is no longer uncommon in the pharmaceutical industry.

.
For example, in March 2020, Laimei Pharmaceutical announced that the company will directly or indirectly hold 100% equity of Hunan Kangyuan, 100% equity of Sichuan Hezheng, 70% equity of Laimei Golden Mouse and 60% equity of Laimei Health.
The Chongqing United Assets and Equity Exchange Group was entrusted with a public listing and transfer with a reserve price of approximately 330 million yuan
.
Regarding the sale transaction, the company stated that it is beneficial to better allocate company resources and improve asset operation efficiency.
It is conducive to the company's development strategy to focus on the advantages of anti-tumor, digestive tract, and anti-infection.
The realization and achievement of the strategic goals of the Ministry of Enterprise
.
Since 2018, in order to improve asset operation efficiency and anti-risk capabilities, Renfu Pharmaceutical has firmly implemented the "re-cored" strategy, actively promoted business focus and asset optimization, and decided to gradually withdraw from medical services, etc.
Segmented areas where the competitive advantage is not obvious or the synergy effect is weak
.
It disclosed in the 2020 semi-annual report that in order to continuously divest non-core pharmaceutical assets, continue to optimize its business and capital structure, and to achieve business focus, the company sold a 70% stake in another holding subsidiary, Sichuan Renfu, for 362 million
.
2020 June 12, Tasly and indirectly controlled by six partnership sold Tianjin Tasly Pharmaceutical Marketing Group Co.
, Ltd.
(99.
9448%) equity interest in Chongqing Pharmaceutical (Group) Co.
, Ltd
.
Among them, the listed company Tasly intends to sell 88.
4937% of its shares in Tianshi Marketing to Chongqing Pharmaceuticals, and the 6 partnerships indirectly controlled by the listed companies intend to sell their total 11.
4511% of its shares in Tianshi Marketing to Chongqing Pharmaceuticals
.
The industry pointed out that in the context of the continuous introduction of industry policies such as volume procurement, payment by disease, and restrictions on auxiliary drugs, the pharmaceutical market structure has changed, and industry competition has become more intense, forcing pharmaceutical companies to accelerate transformation and upgrading, and through the sale of non-core Asset focus on core business has become a choice for pharmaceutical companies
.
In this way, it is beneficial for pharmaceutical companies to revitalize their assets, optimize resource allocation, focus on core business, and control operating risks; at the same time, it is also conducive to improving the company's own financial status, increasing corporate profits, and optimizing financial statements
.